한글목차

총상 신경섬유종 치료 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 14억 5,000만 달러에서 2026년에는 15억 7,000만 달러에 이르고, CAGR 8.4%로 성장할 전망입니다. 지난 수년간의 성장 요인으로는 복잡한 신경초종에 대한 제한된 치료 옵션, 증상 완화를 위한 외과적 개입에 대한 의존도, 낮은 질환 인지도와 진단율, 높은 치료비, 전문 의료시설 부족 등을 꼽을 수 있습니다.

총상 신경섬유종 치료 시장 규모는 향후 몇 년간 견실한 성장이 전망됩니다. 2030년에는 21억 4,000만 달러에 이르고, CAGR은 8.1%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 표적치료 및 정밀의료의 발전, 임상연구 및 의약품 승인 증가, 희귀유전질환에 대한 인식 개선, 소아종양학 서비스 확대, 개인별 맞춤 치료 계획의 통합 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 종양 조절을 위한 표적치료제 채택 증가, 최소침습수술 및 로봇수술의 사용 확대, 소아 환자 맞춤형 치료 접근법에 대한 관심 증가, 병용요법 프로토콜의 확대, 증상 관리 및 삶의 질 개선 등이 있습니다.

개인 맞춤형 의료에 대한 수요 증가는 향후 몇 년 동안 신경섬유종증 치료제 시장의 성장을 견인할 것으로 예측됩니다. 맞춤의료는 환자의 유전자 구성과 분자적 특성에 따라 치료법을 조정하는 것으로, 개별 종양 생물학이나 유전자 변이에 특화된 치료를 가능하게 합니다. 맞춤형 의료의 확대는 희귀질환 환자군과 돌연변이 특이적 치료에 대한 관심이 높아짐에 따라 촉진되고 있습니다. 맞춤의료에 대한 수요 증가는 표적치료제와 정밀의료 전략 개발을 촉진하여 망상신경섬유종 치료의 진전을 가속화하고 있습니다. 이러한 전략은 환자 개개인의 고유한 유전적, 분자적 프로파일에 따라 맞춤형 중재를 통해 치료 효과를 높이고, 부작용을 줄이며, 종양 표현형의 다양성에 대응할 수 있습니다. 예를 들어, 미국에 본사를 둔 전문 회원 단체인 개인화된 의학 연합(Personalized Medicine Coalition)에 따르면, 2024년 2월 현재 미국 식품의약국(FDA)은 26개의 새로운 개인화 치료법을 승인했습니다. 여기에는 20개의 분자 실체와 6개의 유전자 및 세포 기반 치료제가 포함되어 있으며, 이 중 16개는 희귀질환을 대상으로 한 것으로 2022년 승인 건수인 6건의 2배 이상에 달할 전망입니다. 따라서 개인 맞춤형 의료에 대한 수요 증가가 신경섬유종증 치료제 시장의 성장을 견인하고 있습니다.

신경섬유종증 치료제 시장에서 사업을 전개하고 있는 주요 기업들은 치료 효과를 높이기 위해 저분자 억제제 등 첨단 치료 옵션 개발에 집중하고 있습니다. 저분자 억제제는 비정상적인 세포 신호전달 경로에 관여하는 특정 단백질이나 효소를 억제하도록 설계된 저분자 화합물입니다. 예를 들어, 2025년 2월, 미국 바이오 제약사 SpringWorks Therapeutics는 경구용 저분자 MEK 억제제인 Gomekli가 미국 식품의약국(FDA)의 승인을 받았다고 발표했습니다. 고메크리는 신경섬유종증 1형(NF1)을 앓고 있는 성인 및 2세 이상의 소아 환자 중 수술로 완전히 절제할 수 없는 증상성 망상신경섬유종을 가진 환자의 치료에 적용됩니다. 임상시험 결과, 성인 환자의 41%, 소아 환자의 52%에서 종양 크기 감소가 확인되었으며, 성인의 경우 평균 종양 부피가 41%, 소아의 경우 42% 감소했습니다. 또한, 성인 환자의 88%, 소아 환자의 90%에서 12개월 이상 지속되는 반응이 관찰되었으며, 두 그룹 모두 거의 절반의 환자가 24개월 이상 반응을 유지했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Plexiform neurofibroma treatment encompasses medical strategies focused on managing and controlling the growth of complex nerve sheath tumors. The objective is to alleviate symptoms, minimize complications, and enhance quality of life by addressing the effects of the tumor on surrounding tissues and structures.

The main types of treatments for plexiform neurofibroma include surgery, radiation therapy, chemotherapy, and targeted therapy. Surgery is a medical specialty that involves treating injuries, diseases, or other health conditions through manual and instrumental procedures, often requiring incisions to remove, repair, or examine tissues or organs. It is applied for indications such as pain control, tumor reduction, and restoration of function in both pediatric and adult patients. These treatments are utilized by various end users, including hospitals, clinics, and homecare settings.

Tariffs have influenced the plexiform neurofibroma treatment market by increasing the cost of imported pharmaceutical ingredients, advanced surgical equipment, and radiation therapy systems. Targeted therapy drugs and robotic surgery segments are most affected, particularly in regions dependent on imports such as Asia-Pacific and parts of Latin America. These cost pressures can slow treatment adoption and increase healthcare expenditure. However, tariffs also encourage local drug manufacturing, regional clinical research, and domestic production of medical technologies, supporting long-term market growth.

The plexiform neurofibroma treatment market research report is one of a series of new reports from The Business Research Company that provides plexiform neurofibroma treatment market statistics, including plexiform neurofibroma treatment industry global market size, regional shares, competitors with a plexiform neurofibroma treatment market share, detailed plexiform neurofibroma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the plexiform neurofibroma treatment industry. This plexiform neurofibroma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The plexiform neurofibroma treatment market size has grown strongly in recent years. It will grow from $1.45 billion in 2025 to $1.57 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to limited treatment options for complex nerve sheath tumors, reliance on surgical intervention for symptom relief, low disease awareness and diagnosis rates, high treatment costs, limited availability of specialized care centers.

The plexiform neurofibroma treatment market size is expected to see strong growth in the next few years. It will grow to $2.14 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to advancements in targeted and precision therapies, increasing clinical research and drug approvals, growing awareness of rare genetic disorders, expansion of pediatric oncology services, integration of personalized treatment planning. Major trends in the forecast period include rising adoption of targeted therapies for tumor control, increasing use of minimally invasive and robotic surgeries, growing focus on pediatric patient-specific treatment approaches, expansion of combination therapy protocols, improved symptom management and quality of life outcomes.

The growing demand for personalized medicine is anticipated to drive the growth of the plexiform neurofibroma treatment market in the coming years. Personalized medicine involves tailoring medical treatment based on a patient's genetic makeup and molecular characteristics, enabling therapies that are highly specific to individual tumor biology and genetic alterations. The expansion of personalized medicine is fueled by an increasing focus on rare disease populations and mutation-specific therapies. Rising demand for personalized medicine is accelerating progress in plexiform neurofibroma treatment by encouraging the development of targeted therapies and precision-based strategies that customize interventions according to the distinct genetic and molecular profiles of individual patients, thereby improving treatment effectiveness, reducing adverse effects, and addressing variability in tumor presentation. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based professional membership organization, the U.S. Food and Drug Administration approved 26 new personalized treatments, including 20 molecular entities and six gene- or cell-based therapies, with 16 targeting rare diseases-more than double the six approvals recorded in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the plexiform neurofibroma treatment market.

Major companies operating in the plexiform neurofibroma treatment market are concentrating on the development of advanced therapeutic options, such as small-molecule inhibitors, to improve treatment outcomes. Small-molecule inhibitors are low-molecular-weight compounds designed to block specific proteins or enzymes involved in abnormal cellular signaling pathways. For instance, in February 2025, SpringWorks Therapeutics, a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration had approved Gomekli, an oral small-molecule MEK inhibitor. Gomekli is indicated for the treatment of adults and children aged two years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas that cannot be fully removed through surgery. Clinical trial results showed that 41% of adult patients and 52% of pediatric patients achieved a confirmed reduction in tumor size, with an average tumor volume reduction of 41% in adults and 42% in children. In addition, responses lasting at least 12 months were observed in 88% of adults and 90% of children, with nearly half of patients in both groups maintaining their response for more than 24 months.

In April 2025, Merck Group, a Germany-based pharmaceutical company, acquired SpringWorks Therapeutics for $3.4 billion. Through this acquisition, Merck aims to strengthen its healthcare business revenues, accelerate medium- to long-term growth, and expand its presence in the U.S. market. The transaction significantly enhances Merck's portfolio in rare tumors and rare diseases, as SpringWorks contributes two FDA-approved therapies-Ogsiveo for the treatment of desmoid tumors and Gomekli for neurofibromatosis type 1-associated plexiform neurofibromas. SpringWorks Therapeutics is a US-based biopharmaceutical company specializing in treatments for plexiform neurofibroma.

Major companies operating in the plexiform neurofibroma treatment market are SpringWorks Therapeutics, AstraZeneca, Roche Holding AG, Novartis AG, Bayer AG, Eli Lilly and Company, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., AbbVie Inc., Merck KGaA, Ipsen Pharma, Bristol-Myers Squibb, BioMarin Pharmaceutical Inc., Sangamo Therapeutics, Recursion Pharmaceuticals, Day One Biopharmaceuticals, BridgeBio Pharma, Loxo Oncology (Eli Lilly subsidiary), Blueprint Medicines, Kura Oncology, Exelixis Inc., Natera Inc., Amgen Inc., Taiho Pharmaceutical Co. Ltd., Zai Lab Limited, Innovent Biologics, BeiGene Ltd., Deciphera Pharmaceuticals, Cullinan Oncology

North America was the largest region in the plexiform neurofibroma treatment market in 2025. The regions covered in the plexiform neurofibroma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the plexiform neurofibroma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The plexiform neurofibroma treatment market consists of revenues earned by entities by providing services such as genetic testing, clinical evaluation, multidisciplinary care coordination, and clinical trial management. The market value includes the value of related goods sold by the service provider or included within the service offering. The plexiform neurofibroma treatment market also includes sales of tumor monitoring kits, genetic testing kits, clinical decision support tools, and rehabilitation aids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Plexiform Neurofibroma Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses plexiform neurofibroma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for plexiform neurofibroma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The plexiform neurofibroma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy
• 2) By Indication: Pain Management; Tumor Reduction; Functional Restoration
• 3) By Patient Population: Pediatric; Adult
• 4) By End User: Hospitals; Clinics; Home Care Settings
• Subsegments:
• 1) By Surgery: Open Surgery; Minimally Invasive Surgery; Robotic Surgery; Laparoscopic Surgery; Laser Surgery
• 2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Internal Radiation Therapy (Brachytherapy)
• 3) By Chemotherapy: Alkylating Agents; Antimetabolites; Anti-Tumor Antibiotics; Plant Alkaloids; Topoisomerase Inhibitors; Miscellaneous Agents; Combination Chemotherapy
• 4) By Targeted Therapy: Monoclonal Antibodies; Small Molecule Inhibitors; Angiogenesis Inhibitors; Tyrosine Kinase Inhibitors; mTOR Inhibitors; PARP Inhibitors; CDK Inhibitors
• Companies Mentioned: SpringWorks Therapeutics; AstraZeneca; Roche Holding AG; Novartis AG; Bayer AG; Eli Lilly and Company; Pfizer Inc.; Sanofi; Takeda Pharmaceutical Company Limited; Regeneron Pharmaceuticals Inc.; AbbVie Inc.; Merck KGaA; Ipsen Pharma; Bristol-Myers Squibb; BioMarin Pharmaceutical Inc.; Sangamo Therapeutics; Recursion Pharmaceuticals; Day One Biopharmaceuticals; BridgeBio Pharma; Loxo Oncology (Eli Lilly subsidiary); Blueprint Medicines; Kura Oncology; Exelixis Inc.; Natera Inc.; Amgen Inc.; Taiho Pharmaceutical Co. Ltd.; Zai Lab Limited; Innovent Biologics; BeiGene Ltd.; Deciphera Pharmaceuticals; Cullinan Oncology
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Plexiform Neurofibroma Treatment Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Plexiform Neurofibroma Treatment Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Plexiform Neurofibroma Treatment Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Plexiform Neurofibroma Treatment Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Immersive Technologies (Ar/Vr/Xr) & Digital Experiences
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Targeted Therapies For Tumor Control
  • 4.2.2 Increasing Use Of Minimally Invasive And Robotic Surgeries
  • 4.2.3 Growing Focus On Pediatric Patient-Specific Treatment Approaches
  • 4.2.4 Expansion Of Combination Therapy Protocols
  • 4.2.5 Improved Symptom Management And Quality Of Life Outcomes

5. Plexiform Neurofibroma Treatment Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Oncology Centers
• 5.4 Pediatric Care Centers
• 5.5 Home Care Settings

6. Plexiform Neurofibroma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Plexiform Neurofibroma Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Plexiform Neurofibroma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Plexiform Neurofibroma Treatment Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Plexiform Neurofibroma Treatment Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Plexiform Neurofibroma Treatment Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Plexiform Neurofibroma Treatment Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Plexiform Neurofibroma Treatment Market Segmentation

• 9.1. Global Plexiform Neurofibroma Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy
• 9.2. Global Plexiform Neurofibroma Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pain Management, Tumor Reduction, Functional Restoration
• 9.3. Global Plexiform Neurofibroma Treatment Market, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pediatric, Adult
• 9.4. Global Plexiform Neurofibroma Treatment Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Home Care Settings
• 9.5. Global Plexiform Neurofibroma Treatment Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Open Surgery, Minimally Invasive Surgery, Robotic Surgery, Laparoscopic Surgery, Laser Surgery
• 9.6. Global Plexiform Neurofibroma Treatment Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• External Beam Radiation Therapy (EBRT), Internal Radiation Therapy (Brachytherapy)
• 9.7. Global Plexiform Neurofibroma Treatment Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Alkylating Agents, Antimetabolites, Anti-Tumor Antibiotics, Plant Alkaloids, Topoisomerase Inhibitors, Miscellaneous Agents, Combination Chemotherapy
• 9.8. Global Plexiform Neurofibroma Treatment Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monoclonal Antibodies, Small Molecule Inhibitors, Angiogenesis Inhibitors, Tyrosine Kinase Inhibitors, mTOR Inhibitors, PARP Inhibitors, CDK Inhibitors

10. Plexiform Neurofibroma Treatment Market Regional And Country Analysis

• 10.1. Global Plexiform Neurofibroma Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Plexiform Neurofibroma Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Plexiform Neurofibroma Treatment Market

• 11.1. Asia-Pacific Plexiform Neurofibroma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Plexiform Neurofibroma Treatment Market

• 12.1. China Plexiform Neurofibroma Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Plexiform Neurofibroma Treatment Market

• 13.1. India Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Plexiform Neurofibroma Treatment Market

• 14.1. Japan Plexiform Neurofibroma Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Plexiform Neurofibroma Treatment Market

• 15.1. Australia Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Plexiform Neurofibroma Treatment Market

• 16.1. Indonesia Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Plexiform Neurofibroma Treatment Market

• 17.1. South Korea Plexiform Neurofibroma Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Plexiform Neurofibroma Treatment Market

• 18.1. Taiwan Plexiform Neurofibroma Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Plexiform Neurofibroma Treatment Market

• 19.1. South East Asia Plexiform Neurofibroma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Plexiform Neurofibroma Treatment Market

• 20.1. Western Europe Plexiform Neurofibroma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Plexiform Neurofibroma Treatment Market

• 21.1. UK Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Plexiform Neurofibroma Treatment Market

• 22.1. Germany Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Plexiform Neurofibroma Treatment Market

• 23.1. France Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Plexiform Neurofibroma Treatment Market

• 24.1. Italy Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Plexiform Neurofibroma Treatment Market

• 25.1. Spain Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Plexiform Neurofibroma Treatment Market

• 26.1. Eastern Europe Plexiform Neurofibroma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Plexiform Neurofibroma Treatment Market

• 27.1. Russia Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Plexiform Neurofibroma Treatment Market

• 28.1. North America Plexiform Neurofibroma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Plexiform Neurofibroma Treatment Market

• 29.1. USA Plexiform Neurofibroma Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Plexiform Neurofibroma Treatment Market

• 30.1. Canada Plexiform Neurofibroma Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Plexiform Neurofibroma Treatment Market

• 31.1. South America Plexiform Neurofibroma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Plexiform Neurofibroma Treatment Market

• 32.1. Brazil Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Plexiform Neurofibroma Treatment Market

• 33.1. Middle East Plexiform Neurofibroma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Plexiform Neurofibroma Treatment Market

• 34.1. Africa Plexiform Neurofibroma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Plexiform Neurofibroma Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By Patient Population, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Plexiform Neurofibroma Treatment Market Regulatory and Investment Landscape

36. Plexiform Neurofibroma Treatment Market Competitive Landscape And Company Profiles

• 36.1. Plexiform Neurofibroma Treatment Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Plexiform Neurofibroma Treatment Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Plexiform Neurofibroma Treatment Market Company Profiles
  • 36.3.1. SpringWorks Therapeutics Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. AstraZeneca Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

37. Plexiform Neurofibroma Treatment Market Other Major And Innovative Companies

• Eli Lilly and Company, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., AbbVie Inc., Merck KGaA, Ipsen Pharma, Bristol-Myers Squibb, BioMarin Pharmaceutical Inc., Sangamo Therapeutics, Recursion Pharmaceuticals, Day One Biopharmaceuticals, BridgeBio Pharma, Loxo Oncology (Eli Lilly subsidiary)

38. Global Plexiform Neurofibroma Treatment Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Plexiform Neurofibroma Treatment Market

40. Plexiform Neurofibroma Treatment Market High Potential Countries, Segments and Strategies

• 40.1 Plexiform Neurofibroma Treatment Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Plexiform Neurofibroma Treatment Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Plexiform Neurofibroma Treatment Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer